2Lowinger TB,Riedl B,Dumas J,et al.Design and discovery of small molecules targeting raf-1 kinase.Curr Pharm Des,2002,8:2269-2278.
3Hayakawa F,Towatari M,Kiyoi H,et al.Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.Oncogene,2000,19:624-631.
4Levis M,Pham R,Smith BD,et al.In vitro studies of a FLT3 inhibitor combined with chemotherapy:sequence of administration is important to achieve synergistic cytotoxic effects.Blood,2004,104:1145-1150.
5Mori S,Cortes J,Kantarjian H,et al.Potential role of sorafenib in the treatment of acute myeloid leukemia.Leuk Lymphoma,2008,49:2246-2255.
6Kelly LM,Yu JC,Boulton CL,et al.CT 3518,a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).Cancer Cell,2002,1:421-432.
7Stone RM,DeAngelo DJ,Klimek V,et al.Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor,PKC412.Blood,2005,105:54-60.
8DeAngelo DJ,Stone RM,Heaney ML,et al.Phase 1 clinical results with tandutinib (MLN518),a novel FLT3 antagonist,in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome:safety,pharmacokinetics,and pharmacodynamics.Blood,2006,108:3674-3681.
9Knapper S,Burnett AK,Littlewood T,et al.A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701)as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.Blood,2006,108:3262-3270.
10Wilhelm SM,Carter C,Tang L,et al.BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res,2004,64:7099-7109.
